Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

BeiGene doses first patient in Phase II trial of zanubrutinib

MZL is a group of indolent B-cell lymphomas that account for about 8% of all NHL cases. Credit: Librepath.

Go Top